Drug resistance: Prevalence and clinical implications during the treatment of chronic hepatitis C infection
Jean‐Michel Pawlotsky – 26 April 2012 – Watch the interview with the authors
Drug resistance: Prevalence and clinical implications during the treatment of chronic hepatitis C infection
Jean‐Michel Pawlotsky – 26 April 2012 – Watch the interview with the authors
Is there still a role for liver biopsy in managing hepatitis C virus infections?
Syed‐Mohammed R. Jafri, Stuart C. Gordon – 26 April 2012 – Watch the interview with the authors
Management of adverse events during the treatment of chronic hepatitis C infection
Douglas L. Nguyen, Timothy R. Morgan – 26 April 2012 – Watch the interview with the authors
HCV infection on‐treatment viral kinetics: Do they still have a role?
Jordan J. Feld – 26 April 2012 – Watch the interview with the authors
Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing
Diana Vetter, Michal Cohen‐Naftaly, Augusto Villanueva, Youngmin A. Lee, Peri Kocabayoglu, Rebekka Hannivoort, Goutham Narla, Josep M. Llovet, Swan N. Thung, Scott L. Friedman – 26 April 2012 – KLF6‐SV1 (SV1), the major splice variant of KLF6, antagonizes the KLF6 tumor suppressor by an unknown mechanism. Decreased KLF6 expression in human hepatocellular carcinoma (HCC) correlates with increased mortality, but the contribution of increased SV1 is unknown.
Treatment options for anti‐HCV treatment‐experienced patients
Peter Ferenci – 26 April 2012 – Watch the interview with the authors
Predicting the response to the treatment of hepatitis C virus infection
David L. Thomas – 26 April 2012 – Watch the interview with the authors
Managing drug‐drug interactions with boceprevir and telaprevir
Amol S. Rangnekar, Robert J. Fontana – 26 April 2012 – Watch the interview with the authors
Issues in selecting HCV‐infected candidates for anti‐viral treatment
Anna S. Lok – 26 April 2012 – Watch the interview with the authors